Supriya Lifescience Intrinsic Value
Supriya Lifescience (SUPRIYA) median intrinsic value is ₹1035.00 from 9 valuation models (range ₹252–₹1681), vs current price ₹840.50 — +23.1% upside (Trading Below Calculated Value), margin of safety 18.8%. For current market price and key ratios, visit SUPRIYA share price.
SUPRIYA Valuation Methods Summary — DCF, Graham Number & P/E
Supriya Lifescience intrinsic value across 9 models vs current price ₹840.50 — upside/downside and value range per method. Read SUPRIYA dividend track record for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹571.56 | ₹457.25 - ₹685.87 | -32.0% | EPS: ₹25.98, Sector P/E: 22x |
| Book Value Method | asset | ₹1497.50 | ₹1347.75 - ₹1647.25 | +78.2% | Book Value/Share: ₹748.75, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1035.00 | ₹931.50 - ₹1138.50 | +23.1% | Revenue/Share: ₹517.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1681.00 | ₹1512.90 - ₹1849.10 | +100.0% | EBITDA: ₹294.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1400.78 | ₹1120.62 - ₹1680.94 | +66.7% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹252.15 | ₹226.94 - ₹277.37 | -70.0% | EPS Growth: 8.3%, Fair P/E: 6.7x |
| Growth Adjusted P/E | growth | ₹411.88 | ₹370.69 - ₹453.07 | -51.0% | Revenue Growth: 11.4%, Adj P/E: 15.9x |
| ROE Based Valuation | profitability | ₹1681.00 | ₹1512.90 - ₹1849.10 | +100.0% | ROE: 17.8%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹661.58 | ₹595.42 - ₹727.74 | -21.3% | EPS: ₹25.98, BVPS: ₹748.75 |
SUPRIYA Intrinsic Value vs Market Price — All Valuation Models
Supriya Lifescience fair value range ₹252–₹1681 vs current market price ₹840.50 across 9 valuation models. Analyse Supriya Lifescience shareholding analysis to track promoter, FII and institutional holdings.
SUPRIYA Intrinsic Value Analysis — Undervalued or Overvalued?
Supriya Lifescience median intrinsic value ₹1035.00, current price ₹840.50 — Trading Below Calculated Value by 23.1%, margin of safety 18.8%.
What is the intrinsic value of SUPRIYA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Supriya Lifescience (SUPRIYA) is ₹1035.00 (median value). With the current market price of ₹840.50, this represents a +23.1% variance from our estimated fair value.
The valuation range spans from ₹252.15 to ₹1681.00, indicating ₹252.15 - ₹1681.00.
Is SUPRIYA undervalued or overvalued?
Based on our multi-method analysis, Supriya Lifescience (SUPRIYA) appears to be trading below calculated value by approximately 23.1%.
SUPRIYA Financial Health — Key Ratios vs Industry Benchmarks
Supriya Lifescience financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 14.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 17.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 35.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.61x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SUPRIYA Cash Flow Quality — Operating & Free Cash Flow
Supriya Lifescience operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹165 Cr | ₹89 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹113 Cr | ₹26 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹64 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹49 Cr | ₹19 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹76 Cr | ₹53 Cr | Positive Free Cash Flow | 8/10 |